 |
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement Nº 643056. For more information contact BIORAPID coordinator Prof. Jarka Glassey. |
The Rapid Bioprocess Development ITN, employing 15 early stage researchers, brings together industrialist and academic experts with its main aim to address this critical need by developing an effective training framework in a rapid development of novel bioactive molecules from the very early stages of potency and efficacy testing to the biomanufacturing process characterisation and effective monitoring.
The main focus of the research is on oncology-related proteins and recombinant proteins to be used in diabetes treatment, although the resulting monitoring and modelling methods will be applicable to other bioactive molecule process development as demonstrated by validation on a range of relevant bioactives.
| |
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement Nº 643056. For more information contact BIORAPID coordinator Prof. Jarka Glassey. |